Stimulatory Effect of Tofacitinib on Bone Marrow Adipocytes Differentiation.

ABSTRACT:

Background

Systemic inflammation is the main factor underlying secondary osteoporosis in patients with rheumatoid arthritis (RA). Janus kinase inhibitors (JAKi), such as tofacitinib (Tofa), can control systemic inflammation and may have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMAds) are abundant in the bone microenvironment. The effect of JAKi on BMAds is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSC) differentiation routes towards BMAds and osteoblasts (Ob) in osteoporosis.

Objectives

The aims of the study are to determine whether Tofa influences BMAds an

SUBMITTER: Letarouilly JG 

PROVIDER: S-EPMC9299421 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature